SCHEMBL20158751

SCHEMBL20158751

CSN1CCC(C)(C(=O)Nc2ccc(C)nc2)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FPR2 P25090 2/20 0.46
RET P07949 1/20 0.43
GRM5 P41594 2/20 0.40
NPSR1 Q6W5P4 1/20 0.40
KCNQ3 O43525 1/20 0.39
KCNQ2 O43526 1/20 0.39
RAB9A P51151 3/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
NPC1 O15118 2/20 0.39
ALDH1A1 P00352 2/20 0.39
GAA P10253 1/20 0.39
FPR3 P25089 1/20 0.38
MAPT P10636 2/20 0.37
SORT1 Q99523 1/20 0.37
DDX3X O00571 1/20 0.36
NAMPT P43490 1/20 0.36
LIMK2 P53671 1/20 0.36
CNR1 P21554 1/20 0.36
CNR2 P34972 1/20 0.36
HPGD P15428 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20069638 0.86 FPR2 (0.48) FPR2RETGRM5NPSR1KCNQ3
SCHEMBL20205764 0.82 FPR2 (0.46) FPR2RETGRM5NPSR1KCNQ3
SCHEMBL20158752 0.79 RAB9A (0.50) RETRAB9ASMN1; SMN2NPC1ALDH1A1
SCHEMBL21208028 0.71 FPR2 (0.40) FPR2NPSR1RAB9ASMN1; SMN2NPC1
SCHEMBL28544415 0.70 FPR2 (0.51) FPR2GRM5NPSR1KCNQ3KCNQ2
SCHEMBL20069629 0.70 KMT2A (0.50) RETRAB9ASMN1; SMN2NPC1ALDH1A1
SCHEMBL2242286 0.68 NPSR1 (0.57) FPR2GRM5NPSR1KCNQ3KCNQ2
SCHEMBL30919458 0.68 NPSR1 (0.57) FPR2GRM5NPSR1KCNQ3KCNQ2
SCHEMBL20069616 0.68 POLB (0.53) FPR2NPSR1RAB9ASMN1; SMN2NPC1
SCHEMBL31697579 0.68 FPR2 (0.54) FPR2GRM5NPSR1KCNQ3KCNQ2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10172845-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2019-01-08 US disclosed
US-20180134703-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10172845-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, BRAF, RAF1 FPR2 3689/4885RET 1/4885GRM5 1363/4885
US-20180134703-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 FPR2 3689/4885RET 1/4885GRM5 1363/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.